Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 411 |
| CEO | Dr. Michael E. Castagna Pharm.D. |
Contact Details
Address: 1 Casper Street Danbury, Connecticut 06810 United States | |
| Phone | 818-661-5000 |
| Website | mannkindcorp.com |
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| Employer ID | 13-3607736 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | Chief Executive Officer and Director |
| Steven B. Binder | Chief Financial Officer |
| Lauren M. Sabella | Executive Vice President and Chief Operating Officer |
| Dr. David B. Thomson J.D., Ph.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Stuart A. Tross Ph.D. | Executive Vice President and Chief People and Workplace Officer |
| Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |
| Rosabel Realica Alinaya | Vice President of Investor Relations and Treasury |
| John F. Bedard | Senior Vice President of Worldwide Regulatory Affairs |
| James Patrick McCauley Jr., J.D., M.B.A. | Chief Commercial Officer |
| Dr. Burkhard Blank M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | ARS | Filing |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |